Home / Search Results

Search Results

You searched for:

Measurable residual disease (MRD) has gained traction as a compelling marker for disease status across various hematologic malignancies, including multiple myeloma. Learn how MRD is uniquely suited to help evaluate the depth of treatment response.
With data already demonstrating the role of MRD for CLL response assessment and prognosis, cancer programs should prepare themselves for implementation of MRD testing for appropriate patients.
Testing for measurable residual disease can shape treatment choices and patient management to achieve better outcomes, and the need persists for members of the multidisciplinary cancer care team to better understand the purpose, use, and significance of this testing in all cancer treatment settings.
March is Multiple Myeloma Awareness Month. Learn how ACCC is supporting collaboration among healthcare providers with practical, scalable solutions to the real-world challenges of improving quality care delivery for patients with multiple myeloma.